| |
PR NEWSWIRE
09:30 Cohig & Associates, Inc. Initiates Coverage on ImClone Systems, Inc. with a BUY Rating
DENVER, March 23 /PRNewswire/ -- Cohig & Associates, Inc. research analyst Dave Lavigne initiated coverage on ImClone Systems, Inc. (Nasdaq: IMCL) with a BUY rating and a twelve month target price of $13 per share. ImClone is a New York, NY based biotechnology company engaged in the research and development of therapeutic products aimed at the mitigation of cancer and cancer-related disorders. ImClone's product candidates include interventional therapeutics for cancer and cancer vaccines. ImClone has a substantial patent portfolio, which includes 39 international patents and 24 US patents. At the present time, the Company has agreements with several of the largest players in the industry including Merck, Abbott Labs, Chiron and American Home Products. Information and statements contained herein, other than historical information, should be considered forward looking, which involve risk and uncertainties. Cohig and Associates, Inc., its officers, directors and affiliates may maintain positions in the securities referenced which may change at any time without notice. Cohig is a market maker in the common stock of IMCL. The securities referenced are speculative in nature and may not be suitable for your investment objective. Additional information is available upon request. /CONTACT: Dave Lavigne or Billi Hart, both of Cohig & Associates, Inc.,
303-694-0295/
09:30 EST |
|
